Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries

Safety, efficacy and quality of manufacturing are mandatory for all new drugs [1 –3]. The reimbursement from public finances is linked to discussions on cost-effectiveness, financial risk-sharing and solidarity [4,5]. Likewise, the quality of usage of medicines is an important prerequisite for effectiveness [6,7] and the public payer-purchasing price should contribute to fisca l sustainability [6,8]. Consequently, we believe these four focal points of regulation and governance are inter-related and overlap as is illustrated in the Venn-diagram we developed for this study, to help positioning our topic: managed entry agreements (MEAs) (see Fig.

Source: Health Policy - January 11, 2018 Category: Health Management Authors: Alexandru M. Rotar, Alin Preda, Olga L öblová, Vanesa Benkovic, Szymon Zawodnik, Laszlo Gulacsi, Maciej Niewada, Imre Boncz, Guenka Petrova, Maria Dimitrova, Niek Klazinga Source Type: research